Maravai LifeSciences Holdings Balance Sheet Health
Financial Health criteria checks 4/6
Maravai LifeSciences Holdings has a total shareholder equity of $613.1M and total debt of $521.7M, which brings its debt-to-equity ratio to 85.1%. Its total assets and total liabilities are $1.3B and $665.1M respectively.
Key information
85.1%
Debt to equity ratio
US$521.72m
Debt
| Interest coverage ratio | n/a |
| Cash | US$578.16m |
| Equity | US$613.13m |
| Total liabilities | US$665.09m |
| Total assets | US$1.28b |
Recent financial health updates
Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Oct 15
Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Jul 15Recent updates
Maravai LifeSciences: Still Struggling To Find Its Footing
Nov 25Slammed 37% Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Screens Well Here But There Might Be A Catch
Nov 11Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Oct 15Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors
Jul 18Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Jul 15Maravai: Embedded Expectations Remain Too High Considering Economic Calculus
Jul 12RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One
Jun 12Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%
May 14An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Apr 07Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Feb 28Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price
Dec 19Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates
Aug 14Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?
Feb 28Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 01Maravai Lifesciences temporarily reinstates Carl Hull as CEO
Oct 19Maravai LifeSciences appoints former Danaher executive as CEO
Oct 03Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M
Aug 04Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Jun 27Financial Position Analysis
Short Term Liabilities: MRVI's short term assets ($679.1M) exceed its short term liabilities ($63.2M).
Long Term Liabilities: MRVI's short term assets ($679.1M) exceed its long term liabilities ($601.8M).
Debt to Equity History and Analysis
Debt Level: MRVI has more cash than its total debt.
Reducing Debt: MRVI's debt to equity ratio has reduced from 232% to 85.1% over the past 5 years.
Debt Coverage: MRVI's debt is not well covered by operating cash flow (5.7%).
Interest Coverage: Insufficient data to determine if MRVI's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:06 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Maravai LifeSciences Holdings, Inc. is covered by 17 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Michael Ryskin | BofA Global Research |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |